MARAVAI LIFESCIENCES HLDGS-A (MRVI)

US56600D1072 - Common Stock

5.78  +0.71 (+13.89%)

Premarket: 5.78 0 (0%)

Fundamental Rating

3

Taking everything into account, MRVI scores 3 out of 10 in our fundamental rating. MRVI was compared to 55 industry peers in the Life Sciences Tools & Services industry. The financial health of MRVI is average, but there are quite some concerns on its profitability. While showing a medium growth rate, MRVI is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

MRVI had negative earnings in the past year.
MRVI had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MRVI reported negative net income in multiple years.
In the past 5 years MRVI always reported a positive cash flow from operatings.

1.2 Ratios

Looking at the Return On Assets, with a value of -9.13%, MRVI is in line with its industry, outperforming 52.73% of the companies in the same industry.
MRVI has a Return On Equity of -30.24%. This is comparable to the rest of the industry: MRVI outperforms 41.82% of its industry peers.
Industry RankSector Rank
ROA -9.13%
ROE -30.24%
ROIC N/A
ROA(3y)3.71%
ROA(5y)3.14%
ROE(3y)23.17%
ROE(5y)30.08%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of MRVI (46.73%) is comparable to the rest of the industry.
MRVI's Gross Margin has been stable in the last couple of years.
MRVI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.3%
GM growth 5Y-0.98%

More info and screens

4

2. Health

2.1 Basic Checks

MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRVI has less shares outstanding
Compared to 5 years ago, MRVI has less shares outstanding
Compared to 1 year ago, MRVI has a worse debt to assets ratio.

2.2 Solvency

MRVI has an Altman-Z score of 1.62. This is a bad value and indicates that MRVI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.62, MRVI is in line with its industry, outperforming 47.27% of the companies in the same industry.
A Debt/Equity ratio of 1.26 is on the high side and indicates that MRVI has dependencies on debt financing.
With a Debt to Equity ratio value of 1.26, MRVI is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Altman-Z 1.62
ROIC/WACCN/A
WACC10.57%

2.3 Liquidity

A Current Ratio of 10.00 indicates that MRVI has no problem at all paying its short term obligations.
MRVI's Current ratio of 10.00 is amongst the best of the industry. MRVI outperforms 94.55% of its industry peers.
MRVI has a Quick Ratio of 9.28. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MRVI (9.28) is better than 92.73% of its industry peers.
Industry RankSector Rank
Current Ratio 10
Quick Ratio 9.28

More info and screens

4

3. Growth

3.1 Past

MRVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -108.11%.
The Revenue for MRVI has decreased by -67.28% in the past year. This is quite bad
The Revenue has been growing by 18.47% on average over the past years. This is quite good.
EPS 1Y (TTM)-108.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-67.28%
Revenue growth 3Y0.57%
Revenue growth 5Y18.47%
Sales Q2Q%-2.49%

3.2 Future

MRVI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 66.82% yearly.
MRVI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.08% yearly.
EPS Next Y-254.33%
EPS Next 2Y-20.78%
EPS Next 3Y45.83%
EPS Next 5Y66.82%
Revenue Next Year-3.3%
Revenue Next 2Y1.77%
Revenue Next 3Y5.96%
Revenue Next 5Y14.08%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRVI. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 306.97, MRVI can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MRVI is on the same level as its industry peers.
MRVI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.98.
Industry RankSector Rank
PE N/A
Fwd PE 306.97

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MRVI is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7755.01

4.3 Compensation for Growth

MRVI's earnings are expected to grow with 45.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.78%
EPS Next 3Y45.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (11/11/2024, 8:00:01 PM)

Premarket: 5.78 0 (0%)

5.78

+0.71 (+13.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.46B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 306.97
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.13%
ROE -30.24%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 46.73%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 10
Quick Ratio 9.28
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-108.11%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-254.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-67.28%
Revenue growth 3Y0.57%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y